Systemic venous thrombosis after recombinant factor VIIa in the control of bleeding after cardiac surgery.
Recombinant factor VIIa has been licensed in the United Kingdom since 1996 for the control of bleeding in hemophilic patients who are actively bleeding or are about to undergo surgery. Medical practitioners are also applying recombinant factor VIIa toward the control of bleeding in patients without hemophilia. Although the efficacy of recombinant factor VIIa has been shown in many patients, concerns have arisen about the risk of thrombotic adverse events. Herein, we report the case of a 73-year-old woman who underwent major coronary surgery and developed fatal systemic venous thrombosis after recombinant factor VIIa was used in an attempt to control her severe postoperative bleeding. We review the medical literature and discuss the risks of using recombinant factor VIIa to control severe bleeding after cardiac surgery.
Mahmoud
Amr
A
Leeds General Infirmary, Leeds LS1 3EX, United Kingdom.
Al-Ruzzeh
Sharif
S
McKeague
Helena
H
Cross
Mike
M
D000368:Aged; D001026:Coronary Artery Bypass / Q000379:methods*; D015942:Factor VIIa / Q000009:adverse effects* / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007601:Jugular Veins; D019106:Postoperative Hemorrhage / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D013350:Subclavian Vein; D020246:Venous Thrombosis / Q000139:chemically induced* / Q000175:diagnosis
D011994:Recombinant Proteins; C103587:recombinant FVIIa; D015942:Factor VIIa